Skip to content

Drug interactions

Belzutifan + Doxorubicin

Severity: Minor

Belzutifan and Doxorubicin: minor interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Belzutifan is a weak CYP3A4 inducer and may lower exposure to CYP3A4 substrates. CYP3A4 is a minor route for doxorubicin, so any loss of effect is likely small.

What this interaction means in plain words

Belzutifan and Doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.

Belzutifan belongs to Miscellaneous; Doxorubicin belongs to Oncology.

Evidence level: Low

Why it happens

Belzutifan induces CYP3A4, possibly modestly increasing doxorubicin metabolism.

What to do

No routine dose change is needed. Monitor for reduced response to doxorubicin.

What to ask your pharmacist

  • Is there anything I should notice while taking both?
  • Do I need to tell my doctor at the next visit?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Belzutifan and Doxorubicin, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Belzutifan with Doxorubicin?

MediHelp rates the interaction as minor. Belzutifan and Doxorubicin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Belzutifan is a weak CYP3A4 inducer and may lower exposure to CYP3A4 substrates. CYP3A4 is a minor route for doxorubicin, so any loss of effect is likely small.

How serious is the interaction between Belzutifan and Doxorubicin?

MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No routine dose change is needed. Monitor for reduced response to doxorubicin.

What other medicines interact with Doxorubicin?

MediHelp also lists interactions of Doxorubicin with, for example, Adenovirus types 4 and 7 live, Belatacept, Cobicistat. The full list is on the Doxorubicin page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in